Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
Frank A SinicropeQian ShiAurelie CatteauGraham M PoageTyler J ZemlaBernhard MlecnikAl Bowen BensonSharlene GillRichard M GoldbergMorton S KahlenbergSuresh G NairAnthony Frank ShieldsThomas C SmyrkJerome GalonSteven R AlbertsPublished in: JCO precision oncology (2022)
Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making.